BRNS

Barinthus Biotherapeutics plc (BRNS) ESG Analysis Analysis (2026)

Invetso Score: 5.9/10 — Balanced · Last Updated: 2026-09-01

Environmental

No disclosed R&D intensity or emissions metrics are provided, leaving BRNS less transparent than peers with clearer environmental reporting and targets.

The absence of capital-allocation data tied to low-carbon or resource-efficiency initiatives limits evidence of environmental transition readiness versus better-disclosed peers.

Zero reported gross profit margin in the supplied metrics suggests limited operating cushion to fund environmental programs, though this is not a direct ESG indicator.

Without verified environmental disclosures on energy use, waste, or climate governance, BRNS cannot be assessed as a leader relative to peers with fuller filings.

Social

No workforce, safety, or turnover metrics are provided, so BRNS appears less transparent than peers that disclose core human-capital indicators.

The absence of stock-based compensation in the supplied data may indicate lower dilution pressure, but it does not materially evidence stronger employee alignment than peers.

Limited disclosure on labor practices, diversity, and community impact constrains confidence in BRNS's social positioning versus more transparent peer companies.

With no reported social controversies in the provided information, BRNS avoids a clear disadvantage, but its peer-relative profile remains only moderate.

Governance

Debt-to-equity of 0.18 and net debt-to-EBITDA of 1.31 indicate moderate leverage, which is generally less governance-stretching than highly levered peers.

Zero stock-based compensation to revenue suggests restrained equity dilution, supporting capital-discipline optics relative to peers with heavier compensation burdens.

However, the provided data do not include board independence, audit quality, or shareholder-rights disclosures, limiting evidence of stronger governance versus peers.

Overall governance appears acceptable rather than leading, because leverage is manageable but disclosure depth is insufficient to distinguish BRNS from better-governed peers.

Overall Score

BRNS screens as a moderately positioned ESG name versus peers, with acceptable leverage discipline but limited disclosure depth across environmental and social dimensions.

Score Driver: Limited ESG Disclosure Transparency Relative To Peers

Sources

  • Company filings (10-K, 10-Q, investor presentations)
  • Financial and market data providers
  • Public news and industry information

🔒 Go Beyond This Framework

This is one of 10 institutional-grade frameworks Invetso runs on Barinthus Biotherapeutics plc. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

Create your free account on Invetso →